Drug Origin Transparency Act of 2026

Key Points

• Drug companies would have to report detailed supply chain information to the government, including the identity of every supplier for each active ingredient, intermediate, and in-process material used to make a drug.
• Companies would also have to report the specific amounts of a drug produced using ingredients from each identified supplier, giving the government a much clearer picture of where medicines actually come from.
• Instead of reporting just once a year, drug makers could be required to submit supply chain updates up to four times per year, helping the government spot problems faster.
• Medicine labels would need to show the name, location, and unique facility identifier of the original manufacturer of the drug or active ingredient, so patients and doctors can see where their medicine was made.
• The new reporting requirements would not kick in until at least six months after the government finalizes its rules, giving companies time to adjust their systems.
• The bill has bipartisan support, introduced by Reps. Matsui, Crenshaw, Schrier, and Hinson, and was referred to the House Energy and Commerce Committee.